Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis (ACRIBiS) as part of the medical informatics initiative

Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis (ACRIBiS) as part of the medical informatics initiative - ACRIBiS-Cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034792

Enrollment

5250

Registered

2024-09-02

Start date

2024-10-14

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

At least one of the following diagnoses o Diagnosis of manifest arteriosclerotic cardiovascular disease in the medical history as defined below: Acute myocardial infarction (ICD: I21), acute coronary syndrome (ICD: I24), coronary and arterial revascularization (bypass surgery (OPS: 5-361, 5-362), vascular angioplasty (OPS: 8-836.0, 8-36.1, 836. 2)), proven arteriosclerosis in imaging (coronary angiography (OPS: 1-275), arterial ultrasound), stroke (ICD: I63), TIA (ICD: G45.9), aortic aneurysm (

Interventions

Group 1: Documentation of the structured medical history and documentation of diagnoses, biosignals (automatically analyzed ECG data), therapies, medication as part of the clinical routine. Study-spec

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Previously diagnosed cardiovascular disease

Exclusion criteria

Exclusion criteria: Congenital malformations of the heart

Design outcomes

Primary

Measure	Time frame
Primary endpoints (time point: 12 months after study inclusion): - SMART (Second manifestations of arterial disease) risk score: recurrent cardiovascular event (myocardial infarction, stroke, death due to a cardiovascular event) - CHA2DS2VASc risk score (CHA2DS2-VASc Score calculates stroke risk for patients with atrial fibrillation): Stroke - Barcelona Bio-Heart Failure risk calculator: Re-hospitalization due to heart failure, death	—

Measure

Time frame

Primary endpoints (time point: 12 months after study inclusion): - SMART (Second manifestations of arterial disease) risk score: recurrent cardiovascular event (myocardial infarction, stroke, death due to a cardiovascular event) - CHA2DS2VASc risk score (CHA2DS2-VASc Score calculates stroke risk for patients with atrial fibrillation): Stroke - Barcelona Bio-Heart Failure risk calculator: Re-hospitalization due to heart failure, death

—

Secondary

Measure	Time frame
Secondary endpoints: - PROMIS-29 (Patient Reported Outcomes Measurement Information System) - Quality of life: EQ-5D-5L (Patient Reported Outcome (PRO) instrument 5-level EQ-5D version (EQ-5D-5L) from EuroQol) - Further or extended scores for defined domains (voluntary) - Cardiovascular risk - Incident atrial fibrillation/bleeding events in atrial fibrillation (e.g. CHARGE-AF - prediction of atrial fibrillation, HASBLED - estimation of bleeding tendency in anticoagulated patients with atrial fibrillation) - Rehospitalization/mortality in heart failure (e.g. MAGGIC - Risk Score of the Meta-Analysis Global Group in Chronic Heart Failure) - Mortality (e.g. microfragmentation/polyscore)	—

Measure

Time frame

Secondary endpoints: - PROMIS-29 (Patient Reported Outcomes Measurement Information System) - Quality of life: EQ-5D-5L (Patient Reported Outcome (PRO) instrument 5-level EQ-5D version (EQ-5D-5L) from EuroQol) - Further or extended scores for defined domains (voluntary) - Cardiovascular risk - Incident atrial fibrillation/bleeding events in atrial fibrillation (e.g. CHARGE-AF - prediction of atrial fibrillation, HASBLED - estimation of bleeding tendency in anticoagulated patients with atrial fibrillation) - Rehospitalization/mortality in heart failure (e.g. MAGGIC - Risk Score of the Meta-Analysis Global Group in Chronic Heart Failure) - Mortality (e.g. microfragmentation/polyscore)

—

Countries

Germany

Contacts

Public ContactCarina Peter

Universitätsklinikum Bonn

acribis@ukbonn.de+49 151 1685 8007

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026